logo-loader
viewMotif Bio PLC

Motif Bio's lender postpone's loan amortisation date by one month

Hercules Capital made this change in support of Motif Bio managing its cash runway as it advances its pipeline expansion strategy.

Antibiotics
With a meeting planned next month with the FDA, this is an important time for Motif

Motif Bio PLC (LON:MTFB, NASDAQ:MTFB), the antibiotics developer, has amended its financing arrangement with Hercules Capital.

Hercules has agreed to amend the company's loan and security agreement by shifting back the next amortisation by one month to the first day of next month.

This change means that the August payment will be interest only.

READ Motif Bio to meet US regulator on September 19 to discuss trial design

"As we continue to evaluate options to build our pipeline, we are fortunate to have the support of our investors, who understand and appreciate the opportunities that may lay ahead,” said Graham Lumsden, the chief executive officer of Motif.

Quick facts: Motif Bio PLC

Price: 0.95 GBX

AIM:MTFB
Market: AIM
Market Cap: £6.22 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Alkane Resources Ltd's Nic Earner updates on demerger progress and next...

Alkane Resources Limited’s (ASX:ALK) Nic Earner recaps on plans to split subsidiary Australia Strategic Materials which houses their Dubbo project and JV in Korea from its gold business which will remain as Alkane. Earner also updates on work at Tomingley as well as recent results from the...

21 hours, 8 minutes ago

2 min read